TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
EDAP TMS ( (EDAP) ) has shared an announcement.
On November 18, 2025, EDAP TMS S.A. released a report highlighting the significant market opportunity for its Focal One Robotic High-Intensity Focused Ultrasound (HIFU) technology in treating prostate cancer. The company emphasized its strong clinical evidence and superior functional outcomes compared to traditional treatments, positioning Focal One as a leading option in the evolving prostate cancer treatment landscape. This strategic focus is expected to drive growth and expand the company’s presence in the global prostate cancer market.
The most recent analyst rating on (EDAP) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on EDAP TMS stock, see the EDAP Stock Forecast page.
Spark’s Take on EDAP Stock
According to Spark, TipRanks’ AI Analyst, EDAP is a Neutral.
EDAP TMS’s overall stock score is primarily impacted by its financial performance challenges, particularly in profitability and cash flow management. While the earnings call provided some positive insights into revenue growth and strategic advancements, the technical analysis and valuation metrics indicate bearish sentiment and ongoing financial struggles.
To see Spark’s full report on EDAP stock, click here.
More about EDAP TMS
EDAP TMS S.A. is a global leader in the therapeutic ultrasound industry, focusing on the treatment of cancer and benign diseases. The company leverages advancements in imaging, AI, and robotics to address unmet clinical needs, particularly in the urology and prostate cancer markets.
Average Trading Volume: 94,281
Technical Sentiment Signal: Sell
Current Market Cap: $78.52M
For a thorough assessment of EDAP stock, go to TipRanks’ Stock Analysis page.